Founded in 1988, WEGO started a disposable infusion sets business with tax revolving fund of RMB 25,000. At present, it works on developing medical devices and pharmaceuticals as its main business, while expanding the architectural engineering, finance and other businesses. With more than 80 subsidiaries, 2 listed companies, and more than 30,000 employees, WEGO Holding Co., Ltd., which covers an area of more than 6 million square meters, consists of WEGO Group, WEGO Architecture Engneering Group and WEGO Financial Holding Group. WEGO has 12 industry groups including medical products, blood purification, orthopedics, pharmacy, medical commercial, Shengji, Prifills, Jierui blood technology, medical engineering, medical robot. Main businesses of the architecture engneering group include the real estate, building materials, hotels, food and tourism; main businesses of the financial holding group are asset and fund management, credit, equity investment, and securities management. Main products of WEGO are infusion sets, syringes, blood transfusion equipment, intracardiac consumables, IV catheters and special needles, blood purification equipment and consumables, orthopedic materials, operating equipment and accessories, trauma care, surgical robots, minimally invasive devices and equipment, ICU products and accessories, high-capacity injections and other pharmaceuticals, renal products, biological diagnostic reagents, surgical sutures, dental implants, sense control equipment and consumables, PVC & non-PVC materials and so on. With more than 1000 varieties of products provided in more than 150,000 specifications, WEGO’s medical instruments now have entered into 11 fields out of 15 segmented markets, becoming one of the most safe and reliable suppliers of medical system solutions in the world. WEGO has won many honorary titles such as Industrialization Base of Achievements of National High-tech R&D Program of China (863 Program), National Torch Plan Key High-Tech Enterprise, National Intellectual Property Demonstration Enterprise, Leading Enterprise of China's Industry, Top 500 Chinese Enterprises, Top 500 China Credit Enterprises, Top 500 Private Enterprises in China, National Contract Abiding and Trustworthy Enterprise, National Independent Innovation Demonstration Unit, National May 1st Labor Certificate, China Grand Awards for Industry, National Advanced Enterprise Applying Excellence Performance Model, Shandong Governor Quality Award, Chinese Quality Award Nomination and Global Performance Excellence Award. Weihai Blue Ocean Bank Co., Ltd. is approved to operate by the China Banking Regulatory Commission. In 2020, it ranked No. 375 among the top 500 Chinese enterprises, No. 176 among the top 500 Chinese manufacturing enterprises and No. 92 among the top 500 private manufacturing enterprises.
Shandong Wego Interventional Medical Technology Co., LTD., founded within Weihai high-tech science park, which is a subsidiary industrial group under Wego Group Co., LTD. , with approximately 400 employees by now. The industrial group is mainly engaged in the production and operation of interventional devices and consumables.
The industrial Group consists of Shandong Visee Medical Device Co., LTD., Weihai Wego Medical Devices Co., Ltd. , Weihai Gaowei Medical Equipment Co. , Ltd.，Shenzhen Kinhely Bio-Tech Co.,Ltd., Shandong HuaAn Biotechnology Co., Ltd, Shandong Zurich Medical Technology Co., Ltd. and etc. The primary industrial group products cover interventional devices and consumables for coronary interventional therapy, congenital heart disease, cerebrovascular disease, digestive tract and other non-vascular diseases, peripheral vascular diseases and cardiac electrophysiological diseases. Marketed products include cardic stent, balloon, guide wire, heart occluders, filter, non-vascular stents, detachable coil, micro guide wire; central venous catheter, disposable blood pressure transducer and other products.
Shandong Visee Medical Device Co., LTD. ("Visee Medical"), a wholly-owned subsidiary of Wego Group, is a leading domestic devices supplier which combines the research and development, manufacturing and sales of minimally invasive implanted interventional medical devices.
Company's major products:
— heart occluder series for the treatment of congenital heart diseases;
— diagnostic electrophysiology catheter, ablation catheter and other products for the treatment of cardiac electrophysiological diseases;
— products such as Guglialmi detachable coil and stent for the treatment of cerebrovascular diseases;
— inferior vena cava filter system and peripheral coil system for peripheral vascular diseases;
— esophageal and biliary stent for peripheral non-vascular therapy;
— disposable blood pressure transducer and central venous catheterfor intensive care intervention.
Shenzhen Kinhely Bio-Tech Co.,Ltd. was founded in Shenzhen, the innovation capital of China, in 2007. As a nation's high-tech enterprise as well as being an innovative enterprise under Shenzhen Development and Reform Commission's key supporting initiative, the company is committed to the research and development, manufacturing, sales and technical services within the cardiovascular interventional therapy field. Designated by the Major State Basic Research Development Program of China (973 Program), the company developed world first - "Cobalt-based alloy drug-eluting Stent System with Titanium-oxygen Film without substrate coating" and conducted the first prospective, multicenter, randomized controlled clinical trial in China. HELIOS Sirolimus-Eluting Stent were approved by the SFDA and launching on December 26, 2011. The company also won the title of National High-tech Enterprise in October 2013.After WEGO Group acquired the company in 2015, the factory area of the company was expanded to 9,500 square meters, including 3,000 square meters of 10 thousands class cleaning-room. The production capacity was increased while undertakings the research and development of the national key research and development program: "Fully degradable Polymer Scaffold with Vascular Tissue Repair Function”. The company will focus on the field of cardiovascular intervention, providing advanced treatment solutions for clinical use, helping the patients, assiting employees in realizing their personal value, and contributing to the society.More
Shandong HuaAn Biotechnology Co., LTD was founded in February 2008 and registered in Laicheng Industry Park of Laiwu City. It has an area of 66,666 square meters and cofounded by a renowned domestic listed medical device company and an oversea investment firm. It is a high-tech enterprise specializing in the research, development, production and sales of minimally invasive medical devices. The company's research and development team is led by recognized experts in the field of medical and polymer applications, and is committed to the research and development of bio-polymer materials and bioabsorbable vascular stent. It possesses a number of patented technologies that are developed internally.More
NeuroVasc Technologies, Inc. is a developing medical device company headquartered in Irvine, California, USA. Irvine and neighboring cities are also the headquarters location of Medtronic neurointerventional department, Johnson & Johnson neurointerventional department, Balt, and Terumo Neurointerventional department. NeuroVasc Technologies, Inc. was founded in 2015 by the president and CEO, Jim Ma. Since its establishment, the company has been committed to the development and application of new stroke treatment products. The company's new generation articulating segmented clot retriever, micro-catheter, and intermediate catheter products have received European CE mark. Clinical trial of the retriever is scheduled to begin enrollment in China this year. CEO Mr. Ma graduated from Florida International University in the United States. He has been in charge of technology development in ev3, Techwise, and Medtronic peripheral and neurovascular interventional areas, accruing 24 years of medical device work experience. COO Mr. Losordo graduated from the University of Southern California. He worked within Medtronic neurointerventional department and led the research and development of neurointerventional products, accruing more than 10 years of medicl device experience. The articulating segmented clot retriever system developed by NeuroVasc Technologies, Inc. is based on a new patented design that has demonstrated superior performance in laboratory comparative tests and FIM tests.More
Zurich Medical is a developing medical device company with business departments in the state of Minnesota, which is also the location of world-known Mayo Clinic, and the Medtronic, Boston Scientific, and numerous other medical technology companies.
The company was founded in 2013 by President and CEO Paul J. Gam, Chief Operating Officer Kin-Joe Sham, and Vice President of sales and marketing Charles C. Chan. Mr. Gam graduated from Hong Kong Queen's College and the University of Minnesota. He worked at St. Jude and Medtronic. Dr. Sham graduated from MIT and the University of Minnesota in USA. He worked at Orthocor Medical and Boston Scientific. Mr. Chan graduated from Johns Hopkins University and Pepperdine University in USA. He worked at St. Jude and Medtronic.
Zurich Medical is an innovator of cardiovascular devices that are based on proven science and supported by clinical and economic evidence. Its single-use pressure guide wire system is a technology designed for cost effectiveness and ease of use.More
Through advanced and reliable global technology platform, we provide patients with a wide range of various urgently needed vascular interventional products.